G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does not

BACKGROUND: HIV-2 is endemic in West Africa and has spread throughout Europe. However, the alternatives for HIV-2-infected patients are more limited than for HIV-1. Raltegravir, an integrase inhibitor, is active against wild-type HIV-2, with a susceptibility to this drug similar to that of HIV-1, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Xiao-Ju, Delelis, Olivier, Charpentier, Charlotte, Storto, Alexandre, Collin, Gilles, Damond, Florence, Descamps, Diane, Mouscadet, Jean-François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170264/
https://www.ncbi.nlm.nih.gov/pubmed/21854605
http://dx.doi.org/10.1186/1742-4690-8-68

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170264/
https://www.ncbi.nlm.nih.gov/pubmed/21854605
http://dx.doi.org/10.1186/1742-4690-8-68

Ejemplares similares